FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2012064675> ?p ?o ?g. }

• W2012064675 endingPage "870" @default.
• W2012064675 startingPage "859" @default.
• W2012064675 abstract "The racial diversity and gender distribution of HIV-infected patients make it essential to confirm the safety and efficacy of raltegravir in these populations. A multicenter, open-label, single-arm observational study was conducted in a diverse cohort of HIV-infected patients (goals: ≥25% women; ≥50% blacks in the United States), enrolling treatment-experienced patients failing or intolerant to current antiretroviral therapy (ART) and treatment-naive patients (limited to ≤20%). All patients received raltegravir 400 mg b.i.d. in a combination antiretroviral regimen for up to 48 weeks. A total of 206 patients received study treatment at 34 sites in the United States, Brazil, Dominican Republic, Jamaica, and South Africa: 97 (47%) were female and 153 (74%) were black [116 (56%) in the United States]. Of these, 185 patients were treatment experienced: 97 (47%) were failing and 88 (43%) were intolerant to current therapy; 21 patients (10%) were treatment naive. Among treatment-intolerant patients, 55 (63%) had HIV-1 RNA<50 copies/ml at baseline. Overall, 15% of patients discontinued: 13% of men, 18% of women, 14% of blacks, and 17% of nonblacks. At week 48, HIV RNA was <50 copies/ml in 60/94 (64%) patients failing prior therapy, 61/80 (76%) patients intolerant to prior therapy, and 16/21 (76%) treatment-naive patients. Response rates were similar for men vs. women and black vs. nonblack patients. Drug-related clinical adverse events were reported by 8% of men, 18% of women, 14% of blacks, and 9% of nonblacks. After 48 weeks of treatment in a diverse cohort of HIV-infected patients, raltegravir was generally safe and well tolerated with potent efficacy regardless of gender or race." @default.
• W2012064675 created "2016-06-24" @default.
• W2012064675 creator A5013318234 @default.
• W2012064675 creator A5015704931 @default.
• W2012064675 creator A5015849301 @default.
• W2012064675 creator A5018150285 @default.
• W2012064675 creator A5024560316 @default.
• W2012064675 creator A5024756558 @default.
• W2012064675 creator A5038795358 @default.
• W2012064675 creator A5039983859 @default.
• W2012064675 creator A5051538556 @default.
• W2012064675 creator A5069160165 @default.
• W2012064675 creator A5071273581 @default.
• W2012064675 creator A5075198936 @default.
• W2012064675 creator A5079664351 @default.
• W2012064675 creator A5080796048 @default.
• W2012064675 creator A5083402039 @default.
• W2012064675 creator A5083912436 @default.
• W2012064675 creator A5086825885 @default.
• W2012064675 creator A5063362063 @default.
• W2012064675 date "2013-06-01" @default.
• W2012064675 modified "2023-10-14" @default.
• W2012064675 title "Safety, Tolerability, and Efficacy of Raltegravir in a Diverse Cohort of HIV-Infected Patients: 48-Week Results from the REALMRK Study" @default.
• W2012064675 cites W1554813507 @default.
• W2012064675 cites W1973942448 @default.
• W2012064675 cites W1981970084 @default.
• W2012064675 cites W1983837630 @default.
• W2012064675 cites W1988062692 @default.
• W2012064675 cites W1993811071 @default.
• W2012064675 cites W2005214630 @default.
• W2012064675 cites W2008324241 @default.
• W2012064675 cites W2008933891 @default.
• W2012064675 cites W2009692041 @default.
• W2012064675 cites W2016258101 @default.
• W2012064675 cites W2030815382 @default.
• W2012064675 cites W2032800042 @default.
• W2012064675 cites W2045206297 @default.
• W2012064675 cites W2052287045 @default.
• W2012064675 cites W2053125329 @default.
• W2012064675 cites W2056596520 @default.
• W2012064675 cites W2068738256 @default.
• W2012064675 cites W2072487344 @default.
• W2012064675 cites W2092153061 @default.
• W2012064675 cites W2109360985 @default.
• W2012064675 cites W2117678059 @default.
• W2012064675 cites W2119433625 @default.
• W2012064675 cites W2123055341 @default.
• W2012064675 cites W2133425627 @default.
• W2012064675 cites W2135417699 @default.
• W2012064675 cites W2137389341 @default.
• W2012064675 cites W2147210767 @default.
• W2012064675 cites W2150504993 @default.
• W2012064675 cites W2157887699 @default.
• W2012064675 cites W2161993838 @default.
• W2012064675 cites W2182290047 @default.
• W2012064675 cites W2402696555 @default.
• W2012064675 doi "https://doi.org/10.1089/aid.2012.0292" @default.
• W2012064675 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4517411" @default.
• W2012064675 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/23351187" @default.
• W2012064675 hasPublicationYear "2013" @default.
• W2012064675 type Work @default.
• W2012064675 sameAs 2012064675 @default.
• W2012064675 citedByCount "23" @default.
• W2012064675 countsByYear W20120646752012 @default.
• W2012064675 countsByYear W20120646752013 @default.
• W2012064675 countsByYear W20120646752014 @default.
• W2012064675 countsByYear W20120646752015 @default.
• W2012064675 countsByYear W20120646752016 @default.
• W2012064675 countsByYear W20120646752017 @default.
• W2012064675 countsByYear W20120646752018 @default.
• W2012064675 countsByYear W20120646752021 @default.
• W2012064675 crossrefType "journal-article" @default.
• W2012064675 hasAuthorship W2012064675A5013318234 @default.
• W2012064675 hasAuthorship W2012064675A5015704931 @default.
• W2012064675 hasAuthorship W2012064675A5015849301 @default.
• W2012064675 hasAuthorship W2012064675A5018150285 @default.
• W2012064675 hasAuthorship W2012064675A5024560316 @default.
• W2012064675 hasAuthorship W2012064675A5024756558 @default.
• W2012064675 hasAuthorship W2012064675A5038795358 @default.
• W2012064675 hasAuthorship W2012064675A5039983859 @default.
• W2012064675 hasAuthorship W2012064675A5051538556 @default.
• W2012064675 hasAuthorship W2012064675A5063362063 @default.
• W2012064675 hasAuthorship W2012064675A5069160165 @default.
• W2012064675 hasAuthorship W2012064675A5071273581 @default.
• W2012064675 hasAuthorship W2012064675A5075198936 @default.
• W2012064675 hasAuthorship W2012064675A5079664351 @default.
• W2012064675 hasAuthorship W2012064675A5080796048 @default.
• W2012064675 hasAuthorship W2012064675A5083402039 @default.
• W2012064675 hasAuthorship W2012064675A5083912436 @default.
• W2012064675 hasAuthorship W2012064675A5086825885 @default.
• W2012064675 hasBestOaLocation W20120646752 @default.
• W2012064675 hasConcept C126322002 @default.
• W2012064675 hasConcept C142462285 @default.
• W2012064675 hasConcept C197934379 @default.
• W2012064675 hasConcept C201903717 @default.
• W2012064675 hasConcept C203014093 @default.
• W2012064675 hasConcept C2778375690 @default.
• W2012064675 hasConcept C2780404665 @default.

• next